Board of Directors
David Sidransky, MD was appointed the chairman of the board of directors in October 2007. Dr. Sidransky is a renowned oncologist and research scientist named and profiled by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his work with early detection of cancer. Since 1994, Dr. Sidransky has been the director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine and professor of oncology, otolaryngology, cellular & molecular medicine, urology, genetics, and pathology at John Hopkins University and Hospital. During the past decade, in the field of oncology, Dr. Sidransky has been one of the world’s most highly cited researchers in clinic and medical journals, with over 300 peer-reviewed publications. He has contributed more than 40 cancer reviews and chapters. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. He has served as vice chairman of the board of directors, and was, until the merger with Eli Lilly, a director of ImClone Systems Inc., a global biopharmaceutical company committed to advancing oncology care. He is the chairman of Alfacell Corporation and serves on the board of directors of Xenomics. He is serving, and has served, on scientific advisory boards of MedImmune, Roche, Amgen and Veridex, LLC (a Johnson & Johnson diagnostic company), among others. Dr. Sidransky served as director (2005-2008) of the American Association for Cancer Research (AACR). He was the chairperson of AACR International Conferences (2006 and 2007) on Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for Personalized Treatment. Dr. Sidransky is the recipient of a number of awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians, and the 2004 Richard and Hinda Rosenthal Memorial Award from the American Association for Cancer Research.
Joel Ackerman was appointed CEO of Champions Oncology in October 2010. Prior to Champions, he spent 15 years at Warburg Pincus, a leading private equity investment firm, from 1993 to 2008. While at Warburg Pincus, he was a partner of the firm, a member of the executive management group and ran the healthcare services group. He invested in start-ups and early-stage companies as well as later-stage growth investments and management-led buyouts. For most of these companies, Mr. Ackerman served on the board of directors and worked closely with the respective management teams on strategy, financing, M&A and organizational development. Currently, Mr. Ackerman sits on the board of directors of Coventry Health Care, a publicly traded managed care company, and Kindred Healthcare, a publicly traded company that owns hospitals and nursing homes. He is also chairman of the board of One Acre Fund, a nonprofit microfinance organization in Western Kenya. He received a BA in physics from Columbia University and an MA in physics from Harvard University.
Philip Breitfeld, MD has served as Director of the Company since April 2016. Dr. Breitfeld has more than 30 years of experience in oncology and was most recently Global Vice President at Quintiles, responsible for the Therapeutic Centers of Excellence. Prior to that, he led the Oncology Center of Excellence at Quintiles where he worked with many large, mid-size and emerging biopharmaceutical firms. He held senior clinical development positions at Merck KGaA (EMD Serono in the US), where he led oncology development in the US, and at BioCryst, where he led oncology development and was Associate Chief Medical Officer. Prior to his career in industry, he held academic positions at Harvard, University of Massachusetts, Indiana University, and Duke. He has approximately 50 publications in the literature dealing with basic cell and molecular biology, and translational and clinical oncology. He was trained in Pediatric Hematology/Oncology at the Dana-Farber Cancer Institute, was a visiting scientist at the Whitehead Institute at MIT, received his medical degree (MD) from the University of Rochester, and his undergraduate degree (AB in chemistry) from Princeton.
Daniel N. Mendelson has served as a director of the company since March 2013. Mr. Mendelson is the chief executive officer and founder of Avalere Health, a strategic advisory company focused on devising innovative solutions to complex healthcare problems. The firm’s customer base includes Fortune 500 healthcare companies, provider organizations, medical foundations and government. Mr. Mendelson is also on the faculty of the Wharton School of Business at the University of Pennsylvania, and sits on the board of directors of HMS Holdings Corp., a publicly traded company that provides cost containment services to government and private healthcare payers and sponsors. From 1998 to 2000, Mr. Mendelson served as associate director for health at the Office of Management and Budget (OMB). Prior to joining OMB, Mr. Mendelson was senior vice president of The Lewin Group and director of the medical technology practice. He holds an undergraduate degree in economics and viola performance from Oberlin College, and a MPP from the Kennedy School of Government at Harvard University.
Ronnie Morris, MD was appointed president of Champions Oncology in October 2010. Most recently, he was one of the founders of MDVIP, the national leader in personalized healthcare. Serving as a board member, medical director and part of the executive management team, Dr. Morris helped build and manage MDVIP, a company that grew to a network of 400 doctors within 29 states servicing 125,000 consumers/patients. In December 2009, MDVIP was acquired by the Procter and Gamble Co. Prior to MDVIP, Dr. Morris was the chief medical officer and executive VP of AllianceCare, a 1,500-plus-employee company that provided home healthcare, physical therapy and doctor visits for homebound patients. At AllianceCare, Dr. Morris developed and operated the physician house call division of the business, and he was the general medical director for the company. He was the managing partner of a large multispecialty group that was acquired in 1998 by ProMedCo. Dr. Morris is a board-certified internist and until 2004, he had a private practice in Boca Raton, Florida. He has been a consultant for many pharmaceutical companies, including Pfizer, Merck and AstraZeneca.
Abba David Poliakoff is a member of the law firm of Gordon, Feinblatt, Rothman, Hoffberger & Hollander, LLC, in Baltimore, Maryland, chairman of the firm’s Business Department, and a member of the firm’s Electronic Discovery Practice Group. Mr. Poliakoff received his JD degree, magna cum laude, in 1977 from the University of Baltimore Law School, where he was an editor of the University of Baltimore Law Review and associate editor of The University of Baltimore Law Forum. After law school, Mr. Poliakoff joined the staff of the U.S. Securities and Exchange Commission in Washington, D.C., where he became a senior attorney in the Division of Corporation Finance. Mr. Poliakoff is currently a member of the Maryland State Bar Association’s Business Law Section and former chair of its Committee on Securities. Formerly, he was a member of the Business Regulations Article Review Committee of the Committee to Revise the Annotated Code of Maryland. He has been named on Chambers USA’s list of Leading Lawyers for Business since its inception in 2003. Mr. Poliakoff is a member of the board of directors of the Greater Baltimore Technology Council (GBTC) and chair of its Legislative Committee. He is a former chair of the Maryland Business & Technology Coalition, a member of the Tech Council of Maryland and a member of the MIT Enterprise Forum. Mr. Poliakoff is currently the chairman of the Maryland/Israel Development Center, a joint venture between the State of Israel and the state of Maryland collaborating through the Maryland Department of Business and Economic Development and the Israeli Ministry of Industry, Trade and Labor.
Scott R. Tobin has served as director of the company since June 2011. Mr. Tobin joined Battery Ventures, a venture capital firm, in 1997 where he has been a managing partner of various funds affiliated with the firm since May 2000. Prior to joining Battery, Mr. Tobin held positions at First Albany Corp. and at Future Vision, a software company that was sold to SoftKey International. Mr. Tobin has invested in and been active in the management of Battery’s investments in ActivePath, Akamai Technologies, Anobit Technologies, @stake (acquired by Symantec), Istra Research, ITA Software (acquired by Google), Kashya (acquired by EMC), The London International Financial Futures and Options Exchange (LIFFE; acquired by Euronext), MetroPCS, ProfitLogic (acquired by Oracle), Pursway, Sabre, The Tennis Channel, Ximian (acquired by Novell) and Zerto.